Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.9% – Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 6.9% on Monday . The stock traded as high as $8.66 and last traded at $8.34. 12,568,478 shares traded hands during trading, a decline of 13% from the average session volume of 14,385,466 shares. The stock had previously closed at $7.80.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Performance

The firm’s fifty day moving average price is $6.87 and its 200-day moving average price is $7.04. The company has a market cap of $3.17 billion, a P/E ratio of -5.30 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. The company’s revenue was up 147.6% on a year-over-year basis. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total value of $94,800.00. Following the completion of the transaction, the chief financial officer now directly owns 1,426,506 shares of the company’s stock, valued at approximately $9,015,517.92. The trade was a 1.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 70,341 shares of company stock valued at $488,290 over the last ninety days. 15.75% of the stock is owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Axxcess Wealth Management LLC lifted its holdings in Recursion Pharmaceuticals by 4.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after purchasing an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 2.9% during the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after buying an additional 1,800 shares in the last quarter. Amalgamated Bank raised its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after acquiring an additional 2,598 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Recursion Pharmaceuticals by 5.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after acquiring an additional 2,667 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.